TCN e-Systems Connects Global Study Teams with Vital Patient Recruitment Metrics
TCN e-Systems has introduced product enhancements that include mobile connectivity from a smartphone device. The core technology, TrialCentralNetSM, has served as the infrastructure for global and domestic clinical studies, and users are now able to make more rapid business decisions regarding trial management through broader access to real-time recruitment metrics.
“We’ve created a smartphone app to address the needs of clinical teams that rely on our tools for readily accessible, real-time information,” said Sarah Mandracchia, director of data management. “The smartphone app provides access to study-goal information, enrollment numbers, key dates, country information, and media metrics, and study teams can now assess key data and make decisions on the go through their iPhone® or Blackberry®.”
Among the latest enhancements to Version 5.2 is the addition of 11 new languages to the product’s language library.
“With the addition of these languages, we now cover 80 percent of clinical research professionals in their native languages, which will allow site personnel to focus on recruitment efforts and data management. User satisfaction and compliance are certainly expected to benefit as well," Mandracchia said.
The TrialCentralNetSM language library now includes Chinese, Dutch, English, French, German, Hindi, Italian, Japanese, Polish, Portuguese, Russian, and Spanish.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
